Prot #D791PC00001: A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of gefitinib in Combination with MEDI4736 (anti PD-L1) in Subjects with Non-Small Cell Lung Cancer(NSCLC)

Project: Research project

Project Details

StatusFinished
Effective start/end date3/31/16 → 3/31/19

Funding

  • DrugDev Inc. (Prot #D791PC00001 // Prot #D791PC00001)
  • AstraZeneca Pharmaceuticals LP (Prot #D791PC00001 // Prot #D791PC00001)